Prokidney (PROK) Long-Term Deferred Tax (2023)

Prokidney's (PROK) quarterly Long-Term Deferred Tax came in at $1.5 million in Q4 2023.

Prokidney (PROK) Long-Term Deferred Tax (2023) Analysis & Trends

Prokidney (PROK) has 1 years of Long-Term Deferred Tax data on file, last reported at $1.5 million in Q4 2023.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $1.5 million in Q4 2023; TTM through Dec 2023 was $1.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $1.5 million, changed N/A from the prior year.
Long-Term Deferred Tax for Q4 2023 stood at $1.5 million.
Over the last five years, Long-Term Deferred Tax for PROK reached as high as $1.5 million in Q4 2023 and fell as low as $1.5 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Prokidney	96.00 Mn	96.00 Mn	-

Download Data

Date	Value
Dec 31, 2023	1.49 Mn